Switching from ketoconazole to a ciclopirox and zinc pyrithione shampoo significantly reduced hair fall. The user is considering whether to continue using ketoconazole occasionally or combine both shampoos weekly.
The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
The conversation discusses the effectiveness of a "Hair growth complex" pill, with skepticism about its ingredients like saw palmetto and anagain. Users suggest saw palmetto may help slightly with DHT-related hair loss, but it's less effective than finasteride or dutasteride.
Researching the effectiveness of the hair loss treatment Pyril in comparison to other treatments such as Minoxidil, Finasteride, and RU58841. Replies suggest that users often fail to provide updates on their experience with Pyril.
The user is taking 0.5mg finasteride and 0.5mg Loniten orally daily, using Eucapil twice weekly, and Minoxidil foam once daily for hair loss. They believe Eucapil effectively stops hair loss despite side effects like breast growth.
A user is seeking a pharmacy to compound a topical solution containing Minoxidil, Finasteride, Alfatradiol, Melatonin, Latanoprost, and either RU58841 or Pyrilutamide. They prefer a professional compounding lab over DIY methods.
A user was prescribed a topical treatment for hair loss including Latanoprost, Minoxidil, Dutasteride, Hydrocortisone, and Progesterone, after using an oral Minoxidil and Finasteride combo without significant results. Concerns were raised about the long-term use of hydrocortisone, with suggestions to consult a doctor regularly.
Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.
The post and conversation discuss the effectiveness of pyrilutamide for hair loss, with comparisons to finasteride and RU58841. Users express skepticism due to failed trials and high costs, with some waiting for more data before trying pyrilutamide.
The user plans to use RU58841 in the morning and Pyrilutamide in the evening for hair loss treatment, considering replacing Fluridil with Pyrilutamide. They believe Pyrilutamide is effective.
The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
A user beginning to take Pyrilutamide as a treatment for their hair loss, and other users sharing their experiences with the drug or similar treatments such as Minoxidil, Finasteride, and RU58841.
A user's experience with Pyrilutamide for hair loss, which has been successful in reversing receding hairline when part of their stack with other treatments such as Dutasteride, Minoxidil, and Ketoconazole shampoo.
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.
The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.
The conversation discusses potential hair loss treatments, including hair cloning, setipiprant, and topical finasteride, questioning their availability and effectiveness as permanent cures. The user is inquiring about the release dates and efficacy of these treatments.
The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The conversation discusses using Pyrilutamide 1% as a potential treatment for hair loss, with some users combining it with minoxidil and finasteride. Experiences vary, with some reporting shedding and no progress, while others remain hopeful for future results.
A user (seblt) who has had side effects from finasteride, minoxidil and RU58841 but is now trying pyrilutamide as a last resort, with other users providing advice and support. They have already seen some baby hairs growing after 10-14 days of treatment and will provide updates in 1-2 weeks.
The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.
The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.
The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.
The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.